Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody

Toxicol Sci. 2015 Nov;148(1):71-88. doi: 10.1093/toxsci/kfv161. Epub 2015 Aug 4.

Abstract

Nitrogen mustard (NM) is a bifunctional alkylating agent that causes acute injury to the lung that progresses to fibrosis. This is accompanied by a prominent infiltration of macrophages into the lung and upregulation of proinflammatory/profibrotic cytokines including tumor necrosis factor (TNF)α. In these studies, we analyzed the ability of anti-TNFα antibody to mitigate NM-induced lung injury, inflammation, and fibrosis. Treatment of rats with anti-TNFα antibody (15 mg/kg, iv, every 9 days) beginning 30 min after intratracheal administration of NM (0.125 mg/kg) reduced progressive histopathologic alterations in the lung including perivascular and peribronchial edema, macrophage/monocyte infiltration, interstitial thickening, bronchiolization of alveolar walls, fibrin deposition, emphysema, and fibrosis. NM-induced damage to the alveolar-epithelial barrier, measured by bronchoalveolar lavage (BAL) protein and cell content, was also reduced by anti-TNFα antibody, along with expression of the oxidative stress marker, heme oxygenase-1. Whereas the accumulation of proinflammatory/cytotoxic M1 macrophages in the lung in response to NM was suppressed by anti-TNFα antibody, anti-inflammatory/profibrotic M2 macrophages were increased or unchanged. Treatment of rats with anti-TNFα antibody also reduced NM-induced increases in expression of the profibrotic mediator, transforming growth factor-β. This was associated with a reduction in NM-induced collagen deposition in the lung. These data suggest that inhibiting TNFα may represent an efficacious approach to mitigating lung injury induced by mustards.

Keywords: alveolar macrophages; fibrosis; lung injury; vesicant.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alkylating Agents / chemistry
  • Alkylating Agents / toxicity*
  • Animals
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / therapeutic use*
  • Biomarkers / metabolism
  • Chemical Warfare Agents / chemistry
  • Chemical Warfare Agents / toxicity
  • Disease Progression
  • Immunoglobulin G / genetics
  • Immunoglobulin G / metabolism
  • Immunoglobulin G / therapeutic use
  • Lung / drug effects*
  • Lung / immunology
  • Lung / pathology
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Mechlorethamine / antagonists & inhibitors
  • Mechlorethamine / toxicity*
  • Mice
  • Molecular Targeted Therapy
  • Oxidative Stress / drug effects
  • Pulmonary Emphysema / chemically induced
  • Pulmonary Emphysema / drug therapy*
  • Pulmonary Emphysema / pathology
  • Pulmonary Emphysema / physiopathology
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / immunology
  • Pulmonary Fibrosis / prevention & control*
  • Rats, Wistar
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / therapeutic use
  • Respiratory Mucosa / drug effects
  • Respiratory Mucosa / immunology
  • Respiratory Mucosa / pathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Alkylating Agents
  • Antibodies, Monoclonal
  • Biomarkers
  • Chemical Warfare Agents
  • Immunoglobulin G
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Mechlorethamine